A Phase 2 interventional study of JNJ-809 and Apalutamide in Prostatic Neoplasms, Castration-Resistant, sponsored by Janssen Research & Development, LLC. Withdrawn at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-22.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson — 3 open to participants now, 6 under way, 3 of them phase 3. Prostatic Neoplasms, Castration-Resistant · Johnson & Johnson.
Among the 10 studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson, this one is the 10th largest by enrollment, is one of 2 that started in 2016, is one of 2 in phase 2, and was the 4th registered.
85 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 28 are open to participants now.
Browse Prostatic Neoplasms, Castration-Resistant studies →3 of the 10 studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Australia, Belgium and 14 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Australia, Belgium and 14 more countries
Ages 18+ · Men only
Janssen Research & Development, LLC · Sites in Australia, Belgium, Denmark and 12 more countries
Ages 18+
By country, each count listing its studies:
Of the 25 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (88%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 77 across the 10 interventional studies. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
1 of the studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225946Phase 3Janssen Research & Development, LLCA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | 2027-11-19 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate if the anti-tumor activity of JNJ-809 combined with apalutamide is improved compared with apalutamide alone for subjects with metastatic castration-resistant prostate cancer (mCRPC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
JNJ-809 given as an infusion and Apalutamide 240 milligram (mg) daily.
Drug: JNJ-809 · Drug: Apalutamide
Apalutamide 240 mg orally daily.
Drug: Apalutamide
JNJ-809 (1\*10\^9) colony forming units (CFU) given as an infusion.
Apalutamide 240 mg orally daily.
Time to Prostate-specific Antigen (PSA) Progression
Time to PSA progression will be measured using Prostate Cancer Working Group 3 (PCWG3).
Time frame: approximately 2 years
PSA Doubling Time (PSADT)
The PSADT will be determined using the method as recommended by PCWG3 criteria.
Time frame: approximately 2 years
Radiographic Progression-free Survival
Radiographic progression-free survival, is defined as the time from the date of randomization to the date of radiographic progression or death, whichever occurs first.
Time frame: approximately 2 years
Time to Unequivocal Clinical Progression
Time to unequivocal clinical progression defined as the time from the date of randomization to the date of unequivocal clinical progression as evaluated by the investigator.
Time frame: approximately 2 years
Overall Survival
Overall survival defined as time from the date of randomization to death from any cause.
Time frame: approximately 2 years
Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability
Comparison of the AE profiles of the two treatment groups.
Time frame: approximately 2 years
Blood Culture and Shedding Profile of JNJ-809 From Cultured Samples of Feces, Urine, and Saliva
Blood culture samples will be collected after the mandatory prophylactic antibiotic therapy. Bacterial shedding will be evaluated from cultured samples of feces by stool or rectal swab, urine, and sputum.
Time frame: approximately 2 years
The record gives a start of Oct 2016, a primary completion of Sep 2018 and a completion of Sep 2018. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apalutamide
Prostatic Neoplasms, Castration-Resistant →
Janssen Research & Development, LLC →